Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

14,554 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Bone marrow microenvironments that contribute to patient outcomes in newly diagnosed multiple myeloma: A cohort study of patients in the Total Therapy clinical trials.
Danziger SA, McConnell M, Gockley J, Young MH, Rosenthal A, Schmitz F, Reiss DJ, Farmer P, Alapat DV, Singh A, Ashby C, Bauer M, Ren Y, Smith K, Couto SS, van Rhee F, Davies F, Zangari M, Petty N, Orlowski RZ, Dhodapkar MV, Copeland WB, Fox B, Hoering A, Fitch A, Newhall K, Barlogie B, Trotter MWB, Hershberg RM, Walker BA, Dervan AP, Ratushny AV, Morgan GJ. Danziger SA, et al. Among authors: ren y. PLoS Med. 2020 Nov 4;17(11):e1003323. doi: 10.1371/journal.pmed.1003323. eCollection 2020 Nov. PLoS Med. 2020. PMID: 33147277 Free PMC article. Clinical Trial.
Leveraging gene expression subgroups to classify DLBCL patients and select for clinical benefit from a novel agent.
Risueño A, Hagner PR, Towfic F, Fontanillo C, Djebbari A, Parker JS, Drew CP, Nowakowski GS, Maurer MJ, Cerhan JR, Wei X, Ren Y, Lee CW, Couto S, Wang M, Pourdehnad M, Gandhi AK, Trotter MWB. Risueño A, et al. Among authors: ren y. Blood. 2020 Mar 26;135(13):1008-1018. doi: 10.1182/blood.2019002414. Blood. 2020. PMID: 31977005 Free PMC article.
Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets.
Sehgal K, Das R, Zhang L, Verma R, Deng Y, Kocoglu M, Vasquez J, Koduru S, Ren Y, Wang M, Couto S, Breider M, Hansel D, Seropian S, Cooper D, Thakurta A, Yao X, Dhodapkar KM, Dhodapkar MV. Sehgal K, et al. Among authors: ren y. Blood. 2015 Jun 25;125(26):4042-51. doi: 10.1182/blood-2014-11-611426. Epub 2015 Apr 13. Blood. 2015. PMID: 25869284 Free PMC article. Clinical Trial.
Cereblon pathway biomarkers and immune profiles in patients with myeloma receiving post-ASCT lenalidomide maintenance (LEOPARD).
Kalff A, Khong T, Ramachandran M, Walker P, Schwarer A, Roberts AW, Campbell P, Filshie R, Norton S, Reynolds J, Young M, Pierceall W, Thakurta A, Guo M, Oppermann U, Wang M, Ren Y, Kennedy N, Parekh S, Spencer A. Kalff A, et al. Among authors: ren y. Leuk Lymphoma. 2021 Dec;62(12):2981-2991. doi: 10.1080/10428194.2021.1948030. Epub 2021 Jul 15. Leuk Lymphoma. 2021. PMID: 34263697 Clinical Trial.
Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN.
Bjorklund CC, Kang J, Amatangelo M, Polonskaia A, Katz M, Chiu H, Couto S, Wang M, Ren Y, Ortiz M, Towfic F, Flynt JE, Pierceall W, Thakurta A. Bjorklund CC, et al. Among authors: ren y. Leukemia. 2020 Apr;34(4):1197-1201. doi: 10.1038/s41375-019-0620-8. Epub 2019 Nov 12. Leukemia. 2020. PMID: 31719682 Free PMC article. No abstract available.
Cereblon loss and up-regulation of c-Myc are associated with lenalidomide resistance in multiple myeloma patients.
Franssen LE, Nijhof IS, Couto S, Levin MD, Bos GMJ, Broijl A, Klein SK, Ren Y, Wang M, Koene HR, Bloem AC, Beeker A, Faber LM, van der Spek E, Raymakers R, Leguit RJ, Sonneveld P, Zweegman S, Lokhorst H, Mutis T, Thakurta A, Qian X, van de Donk NWCJ. Franssen LE, et al. Among authors: ren y. Haematologica. 2018 Aug;103(8):e368-e371. doi: 10.3324/haematol.2017.186601. Epub 2018 Mar 15. Haematologica. 2018. PMID: 29545338 Free PMC article. No abstract available.
Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4.
Bjorklund CC, Lu L, Kang J, Hagner PR, Havens CG, Amatangelo M, Wang M, Ren Y, Couto S, Breider M, Ning Y, Gandhi AK, Daniel TO, Chopra R, Klippel A, Thakurta AG. Bjorklund CC, et al. Among authors: ren y. Blood Cancer J. 2015 Oct 2;5(10):e354. doi: 10.1038/bcj.2015.66. Blood Cancer J. 2015. PMID: 26430725 Free PMC article.
14,554 results
You have reached the last available page of results. Please see the User Guide for more information.